June 23 (Reuters) - Novo Nordisk said on
Monday the European drugs regulator has adopted a positive
opinion for an update of the Ozempic label to include peripheral
artery disease.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shinjini
Ganguli)